Inovio Pharmaceuticals Inc (INO)

[Opti Mist]

Inovio Pharmaceuticals EPS misses by $0.03, misses on revenue
May 11, 2020 4:11 PM ET|About: Inovio Pharmaceuticals,... (INO)|By: Mohit Manghnani, SA News Editor
Inovio Pharmaceuticals (NASDAQ:INO): Q1 GAAP EPS of -$0.26 misses by $0.03.
Revenue of $1.33M (-52.8% Y/Y) misses by $0.58M.
Shares +2.5%.
Press Release
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
Mon May 11, 2020 4:05 PM|PR Newswire|About: INO
- Phase 2/3 efficacy trial for INO-4800 to start this summer upon regulatory approval
- Preclinical data manuscript for INO-4800 accepted for publication in Nature Communications; Several animal challenge studies currently ongoing
- Additional clinical trials for INO-4800 in China and South Korea to start this summer
- Positive interim data reported for VGX-3100 in Phase 2 clinical trials in precancerous anal and vulvar dysplasias
- INO-3107 advances to Phase 1/2 clinical trial to treat rare, orphan disease recurrent respiratory papillomatosis (RRP)
- 12-month overall survival efficacy data from INO-5401 in GBM to be presented at the American Society of Clinical Oncology (ASCO20)

https://seekingalpha.com/pr/17867054-inovio-reports-first-quarter-2020-financial-results-provides-business-update